Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of a PIKA Rabies Vaccine Containing the PIKA Adjuvant

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Informed consent form has been signed and dated~* Able to attend all scheduled visits and comply with all trial procedures.~* Never received rabies vaccine before.~* Refrain from blood donation during the course of the study.~* Able to attend all scheduled visits and comply with all trial procedures.~Exclusion Criteria:~* For women who are pregnant and breast-feeding~* Previous vaccination against rabies (in pre- or post-exposure regimen) with either the trial vaccine or another vaccine~* History of allergies to the medicine (S), convulsions, epilepsy, mental illness and brain disease and clear serious systemic reaction~* Known bleeding disorder or suspected impairment of immunologic function, or receipt of immunosuppressive therapy or immunoglobulin since birth~* Participation in any other interventional clinical trial~* Donation of blood within the last 2 months or who have donated plasma within the last 14 days~* Patient with clinical signs of encephalitis~* Recipient of any vaccine in the 4 weeks preceding the first trial vaccination, except for influenza vaccination~* Concomitant use or at high probability of expected concomitant use during the planned study of medication such as immune suppressants, steroids, non-study vaccine or similar substances~* Use of any investigational or non-registered drug or vaccine other than the study vaccine(s) within 30 days preceding the first dose of study vaccine, or planned use during the study period.~* Administration of immunoglobulins and/or any blood products within 3 months prior to the first dose of study vaccine or planned administration during the study period.~* History of allergic disease or reactions likely to be exacerbated by any component of the study vaccines.~* Any confirmed or suspected immunosuppressive or immunodeficient condition, including human immunodeficiency virus (HIV) infection.~* Uncontrolled acute or chronic, clinically significant pulmonary, cardiovascular, hepatic or renal functional abnormality, as determined by medical history or physical examination.~* Chronic administration of immuno-suppressants or other immune-modifying drugs within 3 months prior to the first vaccine dose.~* Clinical Manifestation of Metabolic, blood system, lungs, heart, the gastrointestinal tract, nervous system, kidneys, urinary system, endocrine, liver disease or malignant tumor

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Group A (Type: ACTIVE_COMPARATOR): Comparator vaccine RABIPUR®~Healthy volunteers received rabies vaccination intramuscularly on days 0,3,7 and 14
- Group B (Type: EXPERIMENTAL): PIKA Rabies vaccine~Healthy volunteers received rabies vaccination intramuscularly on days 0,3,7 and 14
- Group C (Type: EXPERIMENTAL): PIKA Rabies vaccine with an accelerated regimen~Healthy volunteers received rabies vaccination intramuscularly on days 0 (2 Doses), 3 (2 Doses), and day 7 (1 Dose)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete